6505--RFI - DRAFT SOW for PPV 2028 | SAM.gov Opportunity | G2X

6505--RFI - DRAFT SOW for PPV 2028

Solicitation36E79726Q0003Notice typeSources Sought

Attachments

4 files

Name	Type	Posted	Actions
36E79726Q0003.docx	DOCX	Jun 12, 2026	Download
DRAFT PPV28 Definitions 6-11-2026.pdf	PDF	Jun 12, 2026	Download
DRAFT PPV28 SOW 6-11-2026.pdf	PDF	Jun 12, 2026	Download
DRAFT PPV28 Pricing Categories 6-11-2026.pdf	PDF	Jun 12, 2026	Download

Version History

6505--RFI - DRAFT SOW for PPV 2028

Sources Sought36E79726Q0003Jun 12, 2026 · v1

LatestViewing

Opportunity Summary

The Department of Veterans Affairs (VA) National Acquisition Center is conducting market research to refine the requirements for the Pharmaceutical Prime Vendor (PPV) 2028 program. This Sources Sought notice, identified by solicitation number 36E79726Q0003, requests industry review and feedback on a draft Statement of Work, definitions, and distribution fee categories. The early engagement aims to identify ambiguous requirements and gather suggestions regarding distribution operations, inventory management, data exchange, and order fulfillment processes to ensure the final acquisition supports effective competition and aligns with industry best practices.

This requirement is classified under NAICS 325412, Pharmaceutical Preparation Manufacturing, and PSC 6505, Drugs and Biologicals. The primary objective of the eventual PPV 2028 program is to support the delivery of pharmaceutical products to VA medical centers nationwide. The current notice includes four attachments: a main request for information document, draft definitions, a draft Statement of Work, and draft pricing categories.

Responses are due by July 2, 2026, at 11:00 AM Central Time and should be submitted via email to Karen Ade. Submissions must include company identifiers such as UEI, CAGE code, and socioeconomic designations. This notice is for information and planning purposes only; no contract will be awarded based on this announcement, and participation is voluntary. The VA may contact respondents for clarification of submitted comments to assist in the development of subsequent acquisition documentation.

Generated by Lumen AI

Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.

Opportunity Summary

Opportunity Details

Response deadline: Jul 2, 202620 days remaining
NAICS: 325412 (opens in new tab)
PSC: 6505 (opens in new tab)
Set aside: —
Published: Jun 12, 2026
Updated: Jun 12, 2026
Agency: VETERANS AFFAIRS, DEPARTMENT OF (opens in new tab)
Office: NAC PRIME VENDOR (36W797)
Department: —
Source: View on SAM.gov (opens in new tab)

Contact and place of performance

Point of contact: Karen Ade

Place of performance: Not specified

Original Description

SUBJECT Department of Veterans Affairs Pharmaceutical Prime Vendor 2028 GENERAL INFORMATION CONTRACTING OFFICE S ZIP CODE 60141 SOLICITATION NUMBER 36W79726Q0001 RESPONSE DATE/TIME/ZONE 07-02-2026 11AM CENTRAL TIME, CHICAGO, USA NAICS CODE 325412 CONTRACTING OFFICE ADDRESS Department of Veterans Affairs National Acquisition Center National Contract Service Bldg 37, PO Box 76 60141 POINT OF CONTACT Karen Ade [email protected] 708-786-5231 DESCRIPTION Department of Veterans Affairs Request for Industry Review and Comments on Draft Statement of Work (SOW) Pharmaceutical Prime Vendor (PPV) 2028 The Department of Veterans Affairs (VA) is seeking industry review and feedback on the attached DRAFT Statement of Work (SOW), Definitions and Distribution Fee Categories for the Pharmaceutical Prime Vendor 2028 acquisition. This early engagement is intended to ensure the final SOW is clear, comprehensive and structured to support effective competition from qualified vendors. Industry is invited to provide input including, but not limited to: Identification of unclear, conflicting, or ambiguous requirements Comments on technical or operational requirements that may affect performance Suggestions related to distribution operations, inventory management, reporting, data exchange, or order fulfillment processes Noted risks, barriers, or areas where additional definition would be beneficial Suggestions to improve efficiency, or alignment with industry best practices Industry feedback at this stage helps the VA refine requirements and improve acquisition outcomes. The VA may contact respondents for clarification of submitted comments. Feedback received may be considered in the development of subsequent SOW revisions and acquisition documentation. Participation in this review is voluntary and is not a prerequisite for participation in any future solicitation. Submission Instructions: Provide feedback no later than 11AM Central July 2, 2026 Send responses via email to [email protected] Include the following in your submission: Company Name Point of contact name, phone and email UEI and CAGE Code Socioeconomic designation(s), if applicable Important Notes: This announcement is not a solicitation and does not obligate the Government to issue a solicitation or award. No contract will be awarded from this notice Participation in this review (or lack thereof) does not preclude any vendor from submitting a proposal to the future PPV 2028 solicitation. All feedback will be used for market research and SOW refinement purposes only. The Government will not reimburse any costs associated with providing comments or participating in any related activities. The VA appreciates industry s time and expertise in supporting the development of a strong, effective SOW for the PPV 2028 program. The VA appreciates industry s participation in helping to shape a clear and effective SOW for the PPV 2028 program, which supports delivery of pharmaceutical products to VA medical centers nationwide.